Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $528.90 -3.15%
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.52, $0.25 better than the analyst estimate of $4.27. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.94 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Medicure presents Phase 3 PNPO study data at European Epilepsy Congress
- Barnes & Noble Education (BNED) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
